Modulation of insulin degrading enzyme activity and liver cell proliferation

References

• Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PloS one 2011; 6:e20818; PMID:21695259; http://dx.doi.org/10.1371/journal.pone.0020818
   PubMed Web of Science ®Google Scholar
• Rudovich N, Pivovarova O, Fisher E, Fischer-Rosinsky A, Spranger J, Mohlig M, Schulze MB, Boeing H, Pfeiffer AF. Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes. J Mol Med 2009; 87:1145-51; PMID:19809796; http://dx.doi.org/10.1007/s00109-009-0540-6
   PubMed Web of Science ®Google Scholar
• Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature 2014; 511:94-8; PMID:24847884; http://dx.doi.org/10.1038/nature13297
   PubMed Web of Science ®Google Scholar
• Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PloS one 2010; 5:e10504; PMID:20498699; http://dx.doi.org/10.1371/journal.pone.0010504
   PubMed Web of Science ®Google Scholar
• Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010; 16:3603-15; PMID:20677332; http://dx.doi.org/10.3748/wjg.v16.i29.3603
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49:306-17; PMID:19065650; http://dx.doi.org/10.1002/hep.22603
   PubMed Web of Science ®Google Scholar
• Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10:656-65; PMID:24080776; http://dx.doi.org/10.1038/nrgastro.2013.183
   PubMed Web of Science ®Google Scholar
• Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97:E1170-5; PMID:22563104; http://dx.doi.org/10.1210/jc.2012-1162
   PubMed Web of Science ®Google Scholar
• Valenti L, Dongiovanni P. CDKN1A: a double-edged sword in fatty liver? Cell cycle 2014; 13:1371-2; PMID:24699009; http://dx.doi.org/10.4161/cc.28754
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Wakai T, Hirose Y, Osawa M, Fujimaki S, Kubota M. p27 Is a critical prognostic biomarker in non-alcoholic steatohepatitis-related hepatocellular carcinoma. Int J Mol Sci 2013; 14:23499-515; PMID:24351862; http://dx.doi.org/10.3390/ijms141223499
   PubMed Web of Science ®Google Scholar
• Pihlajamaki J, Boes T, Kim EY, Dearie F, Kim BW, Schroeder J, Mun E, Nasser I, Park PJ, Bianco AC, et al. Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab 2009; 94:3521-9; PMID:19549744; http://dx.doi.org/10.1210/jc.2009-0212
   PubMed Web of Science ®Google Scholar
• Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, Ishikura K, Ando H, Takeshita Y, Ota T, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2010; 12:483-95; PMID:21035759; http://dx.doi.org/10.1016/j.cmet.2010.09.015
   PubMed Web of Science ®Google Scholar
• Rudovich NN, Rochlitz HJ, Pfeiffer AF. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 2004; 53:2359-65; PMID:15331546; http://dx.doi.org/10.2337/diabetes.53.9.2359
   PubMed Web of Science ®Google Scholar
• Pivovarova O, Bernigau W, Bobbert T, Isken F, Mohlig M, Spranger J, Weickert MO, Osterhoff M, Pfeiffer AF, Rudovich N. Hepatic insulin clearance is closely related to metabolic syndrome components. Diabetes Care 2013; 36:3779-85; PMID:24026549; http://dx.doi.org/10.2337/dc12-1203
   PubMed Web of Science ®Google Scholar
• Fawcett J, Sang H, Permana PA, Levy JL, Duckworth WC. Insulin metabolism in human adipocytes from subcutaneous and visceral depots. Biochem Biophys Res Commun 2010; 402:762-6; PMID:21036154; http://dx.doi.org/10.1016/j.bbrc.2010.10.104
   PubMed Web of Science ®Google Scholar
• Pivovarova O, Gogebakan O, Pfeiffer AF, Rudovich N. Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells. Diabetologia 2009; 52:1656-64; PMID:19396426; http://dx.doi.org/10.1007/s00125-009-1350-7
   PubMed Web of Science ®Google Scholar
• Epting CL, King FW, Pedersen A, Zaman J, Ritner C, Bernstein HS. Stem cell antigen-1 localizes to lipid microdomains and associates with insulin degrading enzyme in skeletal myoblasts. J Cell Physiol 2008; 217:250-60; PMID:18506847; http://dx.doi.org/10.1002/jcp.21500
   PubMed Web of Science ®Google Scholar
• Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, Boyer N, Kawarai T, Girardot N, St George-Hyslop P, Checler F. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 2006; 26:6377-85; PMID:16763046; http://dx.doi.org/10.1523/JNEUROSCI.0651-06.2006
   PubMed Web of Science ®Google Scholar
• Bennett RG, Hamel FG, Duckworth WC. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 2003; 52:2315-20; PMID:12941771; http://dx.doi.org/10.2337/diabetes.52.9.2315
   PubMed Web of Science ®Google Scholar
• Fawcett J, Permana PA, Levy JL, Duckworth WC. Regulation of protein degradation by insulin-degrading enzyme: analysis by small interfering RNA-mediated gene silencing. Arch Biochem Biophys 2007; 468:128-33; PMID:17964527; http://dx.doi.org/10.1016/j.abb.2007.09.019
   PubMed Web of Science ®Google Scholar
• Docke S, Lock JF, Birkenfeld AL, Hoppe S, Lieske S, Rieger A, Raschzok N, Sauer IM, Florian S, Osterhoff MA, et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol 2013; 169:547-57; PMID:23935128; http://dx.doi.org/10.1530/EJE-13-0112
   PubMed Web of Science ®Google Scholar
• American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes care 2010; 33 Suppl 1:S62-9.
   PubMed Web of Science ®Google Scholar
• Schurmann C, Heim K, Schillert A, Blankenberg S, Carstensen M, Dorr M, Endlich K, Felix SB, Gieger C, Grallert H, et al. Analyzing illumina gene expression microarray data from different tissues: methodological aspects of data analysis in the metaxpress consortium. PloS one 2012; 7:e50938; PMID:23236413; http://dx.doi.org/10.1371/journal.pone.0050938
   PubMed Web of Science ®Google Scholar
• Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. Limma: linear models for microarray data. New York, Springer, 2005.
   Google Scholar
• Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 1995; 57:289-300.
   Web of Science ®Google Scholar
• Pivovarova O, Jurchott K, Rudovich N, Hornemann S, Lu Y, Mockel S, Murahovschi V, Kessler K, Seltmann AC, Maser-Gluth C, et al. Changes of dietary fat and carbohydrate content alter central and peripheral clock in humans. J Clin Endocrinol Metab 2015:jc20143868; PMID:25822100.
   PubMed Web of Science ®Google Scholar